Press Enter to search · Esc to close
Semaglutide and tirzepatide started as obesity treatments. A wave of moderate-quality evidence is pushing them toward something bigger — and asking new questions about inflammation, the heart, and even cancer.
The shots that started as diabetes drugs and exploded as weight-loss icons are turning out to do a lot more than mute hunger. New research traces their fingerprints across the hindbrain, the kidney's salt switches, and the hormone that tells you it's lunchtime.
A wave of 2025 research suggests GLP-1 agonists are doing more than shrinking waistlines — nudging lipid panels, reshaping fat tissue, and edging into cardiology and dermatology. The signal is real, but still moderate.
New 2025 data suggests GLP-1 receptor agonists are doing more than shrinking waistlines — with signals across the brain, kidneys, and operating room. Here's what the evidence actually says.
Three 2025 studies suggest the new generation of metabolic drugs reaches further than the scale — into addiction risk, liver fat, and the realities of treating people over 65. The evidence is promising, and still maturing.
A new BMJ study using UK primary care data compared GLP-1 users head-to-head with other diabetes drugs — and the suicide-risk signal regulators have been chasing didn't show up.
A new wave of peer-reviewed evidence shows GLP-1 drugs reaching further into metabolic medicine—while exposing risks that busy men should know before they fill the prescription.
A wave of 2025 reviews and trial analyses sketches what comes after tirzepatide — broader populations, bigger weight-loss numbers, and tentative steps into autoimmune diabetes.
Three new reviews argue we've been measuring the wrong thing. The real target isn't weight — it's the adipose tissue quietly running your metabolism.
A major new synthesis argues obesity is not just a metabolic condition but a fundamentally altered immunological state — reshaping how we think about GLP-1s, weight loss, and the body's defenses.